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Millions of craniofacial bone defects occur annually as a result of trauma, 
congenital defects, disease, or tooth extraction1, 2. When present in the oral cavity, 
these defects are associated with adverse impacts on speech, mastication, and 
aesthetics3, 4. Thus, there is a clinical need for interventional strategies to restore and 
preserve alveolar bone mass to improve the success of future treatment options 
intended to reestablish functionality and aesthetics. Guided bone regeneration using 
bone grafts and a membrane represent the current standard of care for repairing 
alveolar bone defects, but face a number of limitations related to resorption time and 
structural integrity. Improvements may be directed toward the development of bone 
graft substitutes that are patient-specific, provide structural support to the defect, and 
promote rapid bone regeneration. Here, we describe the design of a densified, oligomer 
collagen-fibril bone regeneration template inspired by the natural progression of bone 
defect healing. As the dominant component of the bone organic matrix and the soft 
callus formed first during bone fracture healing, type I collagen provides a 
physiologically-relevant material for promoting bone regeneration. The polymerizable 
oligomer collagen formulation preserves fibrillar and suprafibrillar microstructures 
necessary for directing mineral deposition and also facilitates cellular encapsulation 
with minimal shape distortion. The densified oligomer collagen-fibril materials promote 
accelerated and enhanced mineralization by encapsulated human adipose-derived stem 




strategies. This works supports the continued development of oligomer collagen-fibril 




CHAPTER 1. INTRODUCTION 
1.1 A Clinical Need Exists to Preserve and Restore Bone Mass in Alveolar Defects  
Craniofacial bone defects impact a large portion of the western population. Millions of 
individuals experience craniofacial bone defects attributable to trauma, congenital 
abnormalities, cancer treatment, or other diseases1, 2. Additionally, the World Health 
Organization estimates that 240 million people are missing at least one tooth3. 
Approximately 70% of tooth loss is attributable to periodontal disease, a severe 
bacterial infection of the oral tissues3. If left untreated, periodontal disease leads to 
gingival and bone recession and eventually tooth loss. Tooth extraction is also 
performed on over 10 million individuals in the U.S.A. annually due to trauma, dental 
caries, or abscesses3. Bone defects in the oral cavity can negatively impact speech, 
mastication, and aesthetics and can also lead to bone resorption around adjacent teeth3, 
4.  
Clinical interventions such as dental implants strive to restore function and 
aesthetics. Dental implants enable recovery of 85% of the original mastication abilities 
and mitigate the speech and aesthetic complications associated with tooth loss3. The 
continuous application of pressure on the alveolar ridge prevents further bone 
resorption3. Implants have over a 96% success rate provided successful bone 
remodeling occurs to anchor the implant into the host bone3. Implant retention and 
aesthetics are dependent on the quantity and quality of bone available at the defect site. 
In the absence of clinical intervention, defects in the alveolar ridge of the jaw heal but 
can involve significant bone loss that compromises the success of future treatment 




bone mass in order to improve the success of implants intended to reestablish 
functionality and aesthetics3, 7-9. 
 
1.2 Alveolar Bone Exhibits Hierarchical Structures and Follows Normal Mechanisms 
of Bone Repair 
1.2.1 Hierarchical Structure of Bone 
Similar to skeletal bone tissue, craniofacial bone tissue is a highly ordered composite of 
hydroxyapatite mineral (Ca10(PO4)6(OH)2) and an organic matrix, of which 90% is type I 
collagen21, 23. During bone development and regeneration, osteoblasts produce a highly 
collagenous matrix that mediates apatite mineral deposition19. Type I collagen 
molecules are composed of three α-helical chains that supercoil to form a triple helix 
with telopeptide regions on either end19. Side chains on each helix and on the 
telopeptide ends are accessible for binding interactions, contributing to the formation of 
intermolecular crosslinks between collagen molecules and supramolecular assembly 
into highly integrated collagen-fibril matrices19, 24. The type I collagen found in bone 
tissue features pyridinoline and pyrrole crosslinks at the termini of each triple-helix 
molecule23, 25. These intermolecular crosslinks enable collagen molecule self-assembly 
into two-dimensional quarter-staggered arrays with regularly distributed holes and 
overlap zones, which further pack and assemble to create channels. It is within these 
intermolecular spaces that apatite crystal nucleation and growth occur. 
Apatite crystal formation begins within the hole zones of crosslinked collagen 
molecule networks. These collagen molecules, and their higher-order three-dimensional 
arrangement places negatively charged amino acid residues in close proximity, 
particularly within the hole or overlap zones26. Osteoblast-secreted matrix vesicles act 
to increase local saturation of calcium and phosphate ions within the collagen matrix19. 




associate with hydroxyl and carbonyl groups on the collagen strand27. In particular, the 
stereochemical arrangement of carboxylate residues at the telopeptide ends bind 
calcium ions with high affinity26, 27. Strong collagen-ion binding interactions guide the 
preferential orientation of apatite crystals along the crystallographic c-axis and dictate 
the characteristic platelet shape of apatite crystals19, 27. The apatite grows 
independently to fill the regions between the collagen gaps. The mineralized collagen 
matrix is remodeled over time to produce oriented fibrils and the characteristic lamellar 
structure of bone.  
 
1.2.2 Natural Mechanisms of Alveolar Defect Repair 
Alveolar bone defects heal via normal mechanisms of bone repair (Figure 1A). 
Immediately after tooth extraction or loss, an inflammatory response occurs that 
recruits a host of signaling molecules and cells to the defect site5. Mesenchymal stem 
cells, osteoblast precursors, and endothelial cells migrate to the injured tissue during 
the first few days after injury. During the first two weeks, vascularization of the defect 
site occurs to supply nutrients to the wound bed. Additionally, migratory cells 
differentiate into osteoblasts and deposit a collagenous matrix called the osteoid that 
provides a template for mineral formation6. The osteoid is mineralized over the next 
four weeks. The new bone tissue is gradually remodeled during the subsequent months 
to generate a more organized, mature structure. However, the absence of mechanical 
loading at the wound site results in the loss of up to 3 mm (30%) in height and 5 mm 





1.3 A Gap Exists in the Current Standard of Care, Indicating a Remaining Clinical 
Need for Improved Bone Regeneration Strategies 
Clinicians are increasingly utilizing bone regeneration strategies to preserve bone mass 
and to prepare defect sites for future treatment options such as implants. Guided bone 
regeneration (GBR) using a combination of bone grafts and membranes represents the 
standard of care for alveolar defects3, 7, 10. Bone grafts derived from processed cadaver 
or bovine bone stimulate production of vital bone7. Grafts prepared from donor bone 
are osteoinductive (recruits stem cells and induces differentiation) and osteoconductive 
(material properties promote cell growth and bone formation), but not osteogenic (do 
not contain cells that produce bone)1, 11. These bone grafts are packed into the defect 
site then often sealed with a membrane, which stabilizes the graft and acts as a barrier 
to prevent infection and soft tissue invasion7, 10 (Figure 1B). Some membranes (e.g. 
collagen and some synthetic polymers) are resorbed but others (e.g. high-density 
polytetrafluoroethylene) must be removed at a later date3, 10. This type of therapy may 
be used before, or at the same time as, implant placement.  In a staged approach, the 
bone graft is left to stabilize and remodel for 3-6 months before implants are placed7. 
Alternatively, GBR and implant may be placed simultaneously to help expedite the 
healing process7. In these cases, bone grafts are placed to facilitate osteointegration if 
voids between the implant and alveolus measure 2 mm or greater7. 
 The materials used for bone grafts and membranes have been met with 
considerable success but have a number of limitations. The bone grafts are supplied in a 
particulate or putty format, which lack shape retention and structural support to 
maintain the defect site dimensions7. Additionally, cell-mediated resorption of the grafts 
is slow; replacement with vital bone occurs 6-12 months after implantation7. Each of the 
materials used to fabricate membranes is associated with specific benefits and 
limitations7, 10. Nonresorbable membranes fabricated from materials such as high-




bed and providing sufficient mechanical strength to support compressive loading10. 
However, these membranes require surgical removal and increase the cost and pain 
associated with treatment7. Membranes composed from synthetic polymers or collagen 
resorb over time. Synthetic polymer-based membranes may be tuned to exhibit high 
initial structural support12 but the materials rapidly degrade in vivo and the mechanical 
strength is rapidly lost10, 13.  These materials may be fabricated to mimic the nanofiber 
structure of the extracellular matrix but generally have less favorable cell interactions in 
comparison to natural polymers such as collagen12, 14. Collagen-based membranes are 
biocompatible and promote cellular attachment and proliferation15. Conventionally, 
these materials are prepared from a slurry of undissociated, fibrillar type I collagen and 
may be used in combination with growth factors or antibiotics7, 14. However, these 
membranes have low mechanical properties and unpredictable degradation profiles10 
which can present challenges with space maintenance of alveolar defects14, 16. 
Exogenous crosslinking, by chemical or physical means, offers more control over the 
mechanical properties of the membranes but can negatively impact the cellular 
interactions10, 17, 18. Composite collagen/nano-hydroxyapatite scaffolds prepared by 
direct mixing of synthetic nano-hydroxyapatite and insoluble collagen19 have been 
investigated as another method of increasing the mechanical integrity of collagen 
materials15 but were found to exhibit weak binding, leading to unpredictable 
degradation rates and mechanical properties19. Furthermore, the hydroxyapatite 
crystals have no structural similarity to native bone and remain unaltered long after 
implantation, hindering bone formation and remodeling19. After reviewing the clinical 
performance of bone grafts and membranes, the National Institute of Dental and 
Craniofacial Research (NIDCR) indicated that there is still a clinical need for “patient-
specific therapies to repair bone and supporting structures around the teeth and for 





Figure 1: (A) The normal healing sequence for alveolar defects involves extensive bone 
resorption 1 year after tooth loss. (B) Allografts or xenografts in the form of 
(de)mineralized chips or putty are packed into the defect site and covered with a 
membrane. Bone grafting preserves bone mass of the alveolar ridge.  
 
 
1.4 Design Requirements Focus on Replicating Bone Regeneration 
After analyzing the gaps in the current standards of care, three criteria for the design of 
improved bone regeneration therapies intended for alveolar defects were developed: 
patient-specific, physical support for the defect site and implant, and rapid generation 
of high-quality bone tissue. Firstly, the bone graft substitute should be patient-specific9 
in that it may be customized to the dimensions of the bone defect and may be prepared 
to include autologous cells or other components (e.g. antibiotics, growth factors) 
appropriate for the specific case. Secondly, the bone graft substitute should provide 
physical support to the defect site and to the implant9, 11. The material should exhibit 
adequate shape retention and mechanical integrity to support compressive loading and 
maintain the defect site dimensions. Finally, it should rapidly promote the development 
of high-quality, healthy bone tissue that allows for replacement by and integration with 




final form and function of mature bone12, 19 but recent trends have emerged shifting 
focus towards regenerative biology13, 20. Ideally, bone graft substitutes should focus on 
replicating the rapid process of natural bone regeneration and enabling integration with 
surrounding tissue13, 20. As the dominant component of the bone organic matrix21 and 
the soft callus formed as the template in bone defect healing, type I collagen may 
provide an ideal physical and chemical material for bone graft substitutes22. Its excellent 
biocompatibility and cellular interactions encourage host tissue invasion and 
remodeling14. Engineered tissue constructs composed purely of type I collagen might 
reproduce the natural progression of bone development. 
 
1.5 Proposed Solution: A Type I Collagen-Based Bone Regeneration Template 
Polymerizable, soluble collagen formulations facilitate the development of collagen-
based materials that are patient-specific. Alveolar defects vary in size and shape, and 
patient lifestyles or health can impact clinical outcomes associated with bone 
regeneration strategies10. Polymerizable collagen formulations are inherently versatile. 
The polymerizable solutions support injection and polymerization in vivo or can be 
prepared in a mold customized to the specific defect dimensions. This format also 
facilitates the incorporation of cells, growth factors, or other bioactive molecules. Bone 
graft substitutes that contain cells at the time of placement have the potential to 
generate faster and more reliable bone regeneration when compared to acellular 
materials13, 28. Furthermore, polymerizable collagen has been demonstrated to enhance 
cell-matrix interactions15 to promote adhesion, proliferation, and stem cell 
differentiation29, 30. Conventional polymerizable collagen formulations represent 
atelocollagen and telocollagen formulations. Atelocollagen molecules, which are 
isolated by acid extraction in the presence of pepsin, lack telopeptide regions that are 
critical for molecular alignment, intermolecular crosslinking, and mineral formation19, 31. 




supramolecular assembly and interfibril associations, yield matrices consisting of 
entanglements of long individual fibrils. In contrast, oligomeric collagen is an uncommon 
soluble formulation that retains the intramolecular crosslinks found in naturally-
occurring collagen29, 30. Oligomers exhibit rapid fibril and suprafibrillar assembly 
generating highly interconnected collagen-fibril matrices32. Recently, techniques were 
created for the densification of polymerized collagen-fibril matrices33, 34. Densified tissue 
constructs prepared from oligomer collagen-fibril matrices more closely replicate the 
multi-structural features, fibril densities, and mechanical properties of soft tissues found 
in vivo such as the osteoid34. Fabrication of these dense materials support cellular 
encapsulation with cell viability greater than 97%34. Bone regeneration strategies 
prepared from type I collagen that preserves fibrillar and suprafibrillar microstructures 
could promote the natural development of integrated collagen/hydroxyapatite tissues.  
Here, we describe the design of an a polymerizable oligomer collagen-fibril bone 
regeneration template to recreate the unmineralized osteoid and address the clinical 
need for improved bone graft substitutes (Figure 2). The polymerizable collagen 
inherently facilitates dimensional modification for patient-specificity. The work here 
investigates parameters for preparing collagen matrices that facilitate cellular 
encapsulation without significant shape distortion. Human adipose-derived stem cells 
(hASC) were selected as a potential therapeutic source of autologous stem cells with 
established success in craniofacial applications35. The structural properties of the 
densified tissue constructs were determined to assess their capacity to mechanically 
support the alveolar bone defect and the implant. Finally, specific parameters of cell 
density and in vitro osteogenic conditions were optimized to determine the capacity of 
the collagen template to rapidly promote mineralization. The in vitro model was used to 






Figure 2: The ideal strategy meets three design criteria for the regeneration of alveolar 






CHAPTER 2. MATERIALS AND METHODS 
2.1 Preparation of Collagen-Fibril Constructs 
Type I collagen oligomers were acid-solubilized from dermis of market weight pigs, as 
described previously30. Pulverized dermis was extracted with sodium acetate to remove 
soluble non-collagenous proteins and polysaccharides prior to sodium citrate extraction 
of collagen oligomers. Lyophilized oligomer was dissolved in 0.01 N hydrochloric acid 
(HCl) and rendered aseptic by chloroform exposure at 4 °C. Oligomer concentration was 
determined using a Sirius Red (Direct Red 80) assay36. The oligomer formulation was 
standardized based upon molecular composition as well as polymerization capacity 
according to ASTM standard F3089-1432. Here, polymerization capacity is defined by 
matrix shear storage modulus (G′) as a function of oligomer concentration of the 
polymerization reaction. Commercial acid-soluble rat tail collagen (telocollagen) and 
pepsin-solubilized bovine dermis collagen (atelocollagen) were obtained from Corning 
(Corning, NY) and Advanced BioMatrix (Carlsbad, CA), respectively. All collagen solutions 
were diluted with 0.01 N HCl to achieve desired concentrations and neutralized with 10× 
phosphate buffered saline (PBS) and 0.1 N sodium hydroxide (NaOH) to achieve pH 7.437. 
Neutralized solutions were kept on ice prior to cell encapsulation and/or polymerization.  
 
2.2 Cell Culture 
Human adipose-derived stem cells (hASC) were chosen as a potential source of 
autologous cells with improved ease of use and availability compared to bone marrow-
derived stem cells38 that are also capable of robust osteogenic differentiation both in 




as described previously34. Cells were obtained from Zen-Bio (Research Triangle Park, NC) 
and cultured in growth medium consisting of Dulbecco's Modified Eagle Medium 
(DMEM; Life Technologies, Carlsbad, CA), 10% fetal bovine serum (FBS), 100 U/mL 
penicillin, and 100 U/mL streptomyosin (Invitrogen, Grand Island, NY). The hASC were 
grown and maintained in a humidified environment of 5% carbon dioxide in air at 37°C. 
Cells were kept below 80% confluence and used in experiments at passage 6 to 9. 
 
2.3 Preparation of Cellularized Collagen-Fibril Constructs 
Cell-encapsulated collagen-fibril tissue constructs were prepared by suspending hASC in 
neutralized collagen solutions. For studies comparing polymerizable collagen 
formulations, collagen solutions were prepared at 3.0 mg/mL (atelocollgen) to 3.5 
mg/mL (telocollagen and oligomer) and cells were added at a density of 7.5 × 105 
cells/mL. Collagen-cell solutions were aliquoted into individual wells of a 96 well plate 
(150 µL/well) before polymerization for 15 minutes by warming to 37 °C. Tissue 
constructs were cultured with 200 µL osteogenic medium (growth medium 
supplemented with 0.05 mM L-ascorbic acid, 10 mM β-glycerophosphate, and 100 nM 
dexamethasone) for 7-14 days as specified to induce osteogenic differentiation of hASC.  
Medium was changed daily to accommodate the quantity of cells within each matrix. 
Recent work by Blum et al defined methods for the densification of acellular and 
cellular oligomer collagen-fibril matrices to generate tissue constructs with fibril 
densities and mechanical properties similar to soft tissues found in the body34. First, cell-
encapsulated oligomer collagen-fibril matrices were prepared by aliquoting collagen-
hASC suspensions into a 96 well plate (150-342 µL/well) and polymerizing for 15 
minutes by warming to 37 °C. In a high-throughput modification to the method outlined 
by Blum et al, the cellularized matrices were subjected to confined compression using a 
96-well ABS 3D-printed platen (6 mm diameter) at a rate of 6 mm/min to yield densified 




1.5 × 106, or 3 × 107 cells/mL and post-compression collagen-fibril densities were 15, 30, 
or 50 mg/mL as specified. Acellular 50 mg/mL constructs for compressive testing were 
prepared similarly but in the absence of cells. Immediately following densification, 
tissue constructs were transferred to a 48 well plate and 1 mL of medium was added to 
each well. Three types of medium were used: growth medium, osteogenic medium, and 
calcium-supplemented osteogenic medium. Growth medium was used to have an 
unbiased study of the osteoinductivity of the dense collagen-fibril tissue constructs. 
Osteogenic medium was used to induce osteogenic differentiation of hASC by providing 
soluble factors (dexamethasone, ascorbic acid, and β-glycerophosphate) either in 
combination (standard formulation) or individually. Finally, calcium-supplemented 
osteogenic medium, consisting of standard osteogenic medium supplemented with 8 
mM calcium chloride39, was used to provide an additional source of calcium ions 
required for mineral formation. Medium was changed daily to accommodate the 
quantity of cells within each tissue construct. Given the design criteria of inducing rapid 
mineralization, tissue constructs were cultured for a period of 7 days.  
 
2.4 Assessment of Cell-induced Contraction 
Cell-induced contraction of the tissue constructs was determined by measuring the 
reduction in surface area of the cylindrical tissue construct40. Photographs were taken of 
each construct at specified days throughout the experiment and were analyzed using 
ImageJ software made available by the National Institutes of Health. The images were 
used to calculate surface area at the given time point. The calculated surface area was 
normalized to the surface area of an acellular control group measured immediately 





2.5 Histological and Structural Analyses of Tissue Constructs 
For histological characterization, tissue constructs were fixed using 3% 
paraformaldehyde in PBS after 7 days of culture, set in a cryo-embedding compound, 
and frozen for sectioning at 20 µm using a cryostat (Sandon Cryotome FE, Thermo 
Scientific, Waltham, MA). Alizarin Red S (Sigma Aldrich, St. Louis, MO) stain was used to 
detect calcium within the tissue constructs, a marker of osteogenesis and matrix 
mineralization39. Sectioned slides were stained with a 2% Alizarin Red S solution (pH 4.2) 
for 2 minutes then rinsed four times with deionized water to remove any unbound stain. 
Calcium-containing mineralized nodules were stained red and were observed 
qualitatively. Five to six stained sections per group were observed with a Nikon Eclipse 
E2000 microscope (Nikon Instruments, Melville, NY) equipped with a Leica DFC Digital 
Camera (Leica Mircosystems, Wetzlar, Germany). Images were taken at both the center 
and edges of each stained section to observe the spatial and size distribution of 
mineralized regions. 
The microstructure and ultrastructure of collagen-fibril constructs were 
characterized through scanning electron microscopy (SEM). SEM specimens were fixed 
in 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer, post-fixed in 1% osmium 
tetroxide, dehydrated in a graded ethanol series, and critical point dried in a Tousimis 
931 machine.  Dried specimens were coated with platinum in a Cressington 208HR 
sputter coater. One representative sample per group was imaged at several random 
locations using an FEI NOVA nanoSEM 200 field emission scanning electron microscope 
(FEI Company, Hillsboro Oregon) using an ET (Everhart-Thornley) detector or the high-
resolution through-the lens (TLD) detector operating at an accelerating voltage of 5kV, 
spot 3, ~5.0 mm working distance, and 30m aperture. Qualitative observations on 





2.6 Compositional Analysis of Mineralized Tissue Constructs 
Analysis of the chemical composition of minerals within the samples was performed by 
coupling energy-dispersive x-ray spectroscopy (EDX) with SEM. Samples were imaged 
with an FEI Quanta 3D FEG scanning electron microscope (FEI Company, Hillsboro, OR) 
using the Everhart-Thornley (ET) detector at high vacuum. Parameters for imaging were 
5kV, spot 5, 50µm aperture, and working distance of ~10 mm. EDX was done with an 
Oxford INCA Xstream-2 with Xmax80 detector (Oxford Instruments, Peabody, MA) with 
the analytical mode at 10kV, spot 1, 1000µm objective aperture, and a P4 System. The 
“Point and ID” method was used to analyze the atomic composition of three 
representative mineralized regions per culture condition. For each area, spectral peaks 
were used to identify and quantify the specific atoms present within the mineral by 
atomic percent. Raw atomic percent of calcium and phosphate, as well as the calcium to 
phosphate ratio (calculated as the ratio of atomic percent calcium to atomic percent 
phosphate), are displayed as the average ± standard deviation along with a 
representative spectrum.  
MicroCT analysis was performed with a microCT 40 instrument (SANCO Medical 
AG, Switzerland) at 45 kV and 188 µA and a spatial resolution of 6 µm to determine the 
distribution of mineral within the samples after 1 week of culture40. The analysis was 
conducted with a low gray threshold setting of 170 and upper gray threshold of 1000 to 
remove background signal. A 3D reconstruction of the sample was created to observe 
the distribution of dense, mineralized regions throughout the tissue construct. A 
volumetric analysis function was used to calculate the volume fraction of mineralized 
collagen, expressed as the ratio of mineralized volume to total volume (MV/TV, %). 





2.7 Mechanical Testing of Tissue Constructs 
Constructs were tested in unconfined compression at 17%/second to 80% strain using a 
servoelectric materials testing system (Bose, Eden Prairie, MN) adapted with a 40 N load 
cell34. Engineering stress and strain were calculated assuming the tissue constructs 
represent homogenous materials with constant cross-sectional area. Compressive 
modulus was calculated as the slope of the linear region of the stress-strain curve. 
Compression tests were performed on four independent constructs per group. 
 
2.8 Statistical Analysis 
Statistical analysis was performed using Minitab statistical software. Cell-induced 
contraction between collagen formulations was compared using a two-way ANOVA with 
a Tukey post-hoc test; all other comparisons of contraction and mechanical properties 
between construct groups were made by applying a one-way ANOVA with a Tukey post-
hoc test to determine differences in mean values. Calcium-phosphate ratios were 





CHAPTER 3. RESULTS AND DISCUSSION 
3.1 Self-Assembling Oligomer, but not Conventional Collagen Formulations, Possess 
the Necessary Mechanical Integrity and Microstructure to Support Cellular 
Encapsulation and Mineralization 
Pre-formed collagen materials currently utilized as membranes rely upon cellular 
migration and infiltration for mineralization. It has been suggested that materials 
containing cells upon the time of placement have the potential to generate faster and 
more reliable bone formation13, 28, indicating that polymerizable collagen formulations 
amenable to cellular delivery may impact bone regeneration. Our group (T. Smith, 
unpublished) and others have observed similar or expedited bone regeneration rates 
using alternative, polymerizable collagen formulations amenable to cellular 
encapsulation41. Here, we extend this work by comparing the capacity of three collagen 
formulations for cellular delivery. 
Three collagen formulations, differing in their polymerization capacity, were 
utilized to determine an optimal formulation for cellular encapsulation. Here, this was 
defined as resistance to cell-induced matrix contraction. Type I collagen-fibril matrices 
were prepared from commercially available telocollagen and atelocollagen as well as 
laboratory produced oligomer collagen (3.0-3.5 mg/mL). Human adipose-derived stem 
cells (hASC) were encapsulated within these matrices at 7.5x105 cells/mL and cultured 
under standard osteogenic conditions for 14 days42, 43. Significant cell-induced 
contraction was observed for both atelocollagen and telocollagen matrices after 3 days 
of culture (p < 0.001) (Figure 3 A & B). Atelocollagen and telocollagen matrices 
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continued to exhibit significant cell-induced contraction throughout the duration of the 
experiment when compared to the oligomer (p < 0.001). After 14 days, atelocollagen 
and telocollagen matrices had contracted by 92.6 ± 3.3% and 86.1 ± 0.4%, whereas 
oligomer matrices contracted by 4.8 ± 6.5%.  
These results are consistent with previous work describing the importance of 
telopeptide regions and intermolecular crosslinks on supramolecular assembly capacity 
of type I collagen formulations29. As described earlier, atelocollagen molecules lack the 
telopeptide regions critical for molecular alignment and intermolecular crosslinking31. 
Telocollagen formulations retain the telopeptide region but, unable to induce 
supramolecular assembly and interfibril associations, yield matrices consisting of 
entanglements of long individual fibrils. Oligomer collagen formulations retain the 
natural intermolecular crosslinks enabling rapid fibril and suprafibrillar assembly of 
highly interconnected matrices. In comparison to conventional atelocollagen and 
telocollagen formulations, self-assembled oligomer matrices have been found to exhibit 
improved mechanical integrity, resistance to proteolytic degradation and cell-induced 
contraction, and handling capacity29, 44, 45. The differences in microstructure and 
mechanical integrity were observed via cell-mediated matrix contraction. The fibril 
microstructure and associated mechanical properties of self-assembled oligomers 
resists matrix contraction by encapsulated cells and thus are a suitable polymerizable 
collagen formulation for the creation of cellularized tissue constructs.  
Scanning electron microscopy (SEM) was used to validate that the oligomer 
formulation would support mineralization. SEM micrographs of cellularized oligomer 
matrices reveal fibrillar mineralization after 14 days of culture in osteogenic medium 
(Figure 3C). As described previously, several studies have outlined the importance of 
telopeptide regions and gap zones created by collagen crosslinking on the formation of 
apatite crystals19, 26. The oligomer collagen formulation used in this experiment retains 
the hydroxylysinonorleucine intermolecular crosslink associated with its dermal origin44 
which differs from the pyridinoline and deoxypyridinoline crosslinks characteristic of 
type I collagen found in bone25. Mineral deposition appears to depend more upon the 
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presence of a suprafibrillar structure and gap zones between collagen molecules and 
less upon the type of crosslink between them, since oligomer collagen supports cell-
mediated apatite nucleation and crystal growth as occurs in vivo. In comparison, neither 
acellular telocollagen matrices nor cellular matrices cultured in osteogenic medium for 2 
and 4 weeks, respectively, exhibit fibrillar mineralization and instead display localized 




Figure 3: Collagen-fibril matrices of commercial atelocollagen (PureCol) and telocollagen 
(BD Rat Tail) and laboratory-produced oligomer collagen formulations were prepared at 
fibril densities of 3.0-3.5 mg/mL and encapsulated with 7.5x105 hASCs/mL. Collagen 
matrices were cultured in standard osteogenic medium for 14 days. (A) Contraction was 
observed as early as day 3 in atelocollagen and telocollagen matrices. (B) Atelocollagen 
and telocollagen matrices contracted significantly in comparison to the oligomer 
matrices. Letters indicate statistically significant groups (p < 0.05).  (C) SEM micrographs 
of oligomer matrices reveal fibril-level mineralization. 
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3.2 Increasing Collagen-Fibril Density Assists in Dimensional Maintenance with High 
Cell Densities but is not Alone Sufficient to Induce Osteogenesis In Vitro 
Dimensional maintenance of the alveolar ridge motivates ridge augmentation via bone 
graft substitutes. Previous work has shown that increasing oligomer collagen-fibril 
density corresponds to increased mechanical properties, improved shape definition, and 
resistance to cell-induced contraction29. Furthermore, the application of confined 
compression to low-density oligomer collagen fibril matrices yields materials with multi-
scale structural properties similar to those of the soft tissues found in the body, 
including the osteoid34.  
Confined compression was used to create cellularized tissue constructs with 
increasing fibril densities to examine the effect of collagen-fibril density on scaffold 
dimensional maintenance and osteogenic differentiation of encapsulated hASC. 
Cellularized tissue constructs were created by applying plastic compression to hASC-
encapsulated 3.5 mg/mL oligomer matrices to achieve final fibril densities of 3.5, 10, 30, 
and 50 mg/mL and a final cell density of 3𝑥106 cells/mL. Increasing collagen-fibril 
density significantly reduced the extent of cell-induced contraction (p < 0.001) following 
1 week of culture in standard growth medium (Figure 4 A & B). While 3.5 mg/mL 
constructs contracted by 93.2 ± 1.4%, the 50 mg/mL constructs contracted by 7.9 ± 3.5%. 
Increasing fibril density to 50 mg/mL through confined compression provided the 
greatest control over cell-induced contraction and dimensional distortion. 
 The osteogenic differentiation of encapsulated hASC was assessed using Alizarin 
Red, which stains mineralized regions. Calcified nodules are absent at the center of the 
tissue constructs and are sparse at the periphery of 15 and 30 mg/mL groups (Figure 4C). 
Together, these results suggest that while collagen-fibril density may bias hASC toward 
osteogenic differentiation, the dense tissue constructs are not osteoinductive. Soluble 
factors, such as those contained in standard osteogenic differentiation medium, may be 
necessary to provide components (e.g. calcium and phosphate ions) and encourage 
robust mineralization in vitro. These findings are consistent with other work 
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demonstrating that matrix stiffness has an important role in the differentiation of 
multipotent stem cells but is unable to orchestrate a strong osteogenic response 
without the addition of soluble factors29, 46. Increasing fibril density enables cellular 
encapsulation at high cell densities without significant contraction but additional factors 




Figure 4: Human ASC were encapsulated at 3𝑥106 cells/mL within collagen-fibril 
constructs with fibril densities of 3.5, 15, 30, or 50 mg/mL and cultured for 7 days with 
growth medium. (A, B) Collagen constructs with high fibril density exhibit greater 
resistance to cellular contraction as measured by surface area. (C) Alizarin Red staining 
was performed to observe regions of mineralization. Scale bars = 50 µm. Letters indicate 




3.3 Dense, 50 mg/mL Oligomer Constructs Provide a Porous Structure with 
Compressive Modulus Similar to Pre-Mineralized Osteoid 
The osteoid formed during bone development is a dense, collagenous soft tissue 
(compressive modulus 24-40 kPa46) but has a porous structure amenable to host tissue 
invasion and remodeling6, 12.  Highly porous materials prepared from conventional 
collagen formulations are traditionally associated with low mechanical properties 18. 
Various modifications such as chemical and physical crosslinking are applied to increase 
the mechanical performance of collagen materials but often compromise the 
biocompatibility and biological signaling capacity inherent to collagen materials47. 
Densification of collagen scaffolds has been demonstrated as a means of increasing 
mechanical properties without additional chemical or physical crosslinking34 and 
preserves the multi-scale structural features of oligomer collagen matrices33, 34. To 
determine the effect of confined compression on the microstructure and the 
compressive properties of dense oligomer collagen-fibril constructs (50 mg/mL), SEM 
and mechanical analyses were conducted. 
Here the ultrastructure and mechanical properties of 50 mg/mL oligomer 
matrices with and without encapsulated hASC (3x106 cells/mL) were determined. As 
shown in Figure 5A, SEM micrographs of cellular 50 mg/mL constructs revealed an open, 
porous microstructure with interfibril branching. Increasing fibril density brought fibrils 
in closer proximity to one another (as compared to 3.5 mg/mL constructs, Figure 3C) but 
the collagen fibril ultrastructure was not altered. The collagen fibrils are randomly 
oriented and display the characteristic collagen D-banding structure. Scaffolds with 
randomly ordered features with nanoscale topography have been demonstrated to 
direct cellular adhesion, migration, and osteogenic differentiation15, 20. The observations 
on fibril microstructure and porosity are consistent with previous results examining the 
microstructure of 12.25 and 24.5 mg/mL collagen-fibril constructs34.  
Mechanical compression was applied to both acellular and cellular high-density 
(50 mg/mL) tissue constructs to determine the compressive modulus. Representative 
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stress-strain curves for each group, calculated using engineering stress and strain, are 
shown in Figure 4B. The stress-strain curves for both groups showed two distinct regions: 
an initial toe region of nonlinear stress-strain behavior and a linear region. Stress-
relaxation was noted upon cessation of compressive loading. The compressive modulus, 
calculated from the linear region of each curve, did not differ significantly upon cellular 
encapsulation (p = 0.701) (Figure 5 B & C). Acellular constructs had a compressive 
modulus of 31.4±16.0 kPa compared to 26.6±13.4 kPa for tissue constructs 
encapsulated with 3𝑥106 hASC/mL. The compressive modulus for acellular densified 
oligomer constructs differs from expected results from previous studies with densified 
oligomer constructs34, likely due to differences in sample preparation. However, the 
compressive moduli for both cellular and acellular constructs are within the range of 
compressive moduli reported for the pre-mineralized osteoid. The compressive modulus 
for acellular, dense oligomer constructs is similar to what others have found using 
similarly prepared telocollagen constructs (23.5 ± 4.97 kPa)40. The ultrastructure and 
compressive properties of the dense, 50 mg/mL oligomer collagen-fibril constructs 





Figure 5: Oligomer collagen-fibril matrices (50 mg/mL) were prepared with and without 
encapsulated hASC (3𝑥106 cells/mL). (A) SEM micrographs of cellularized constructs 
exhibit a porous microstructure that represents a branched fibril network. (B) 
Representative stress-strain curves for acellular and cellular constructs demonstrating a 
toe and linear region. (C) Compressive moduli for acellular and cellular constructs did 
not differ significantly (p > 0.05).  
 
3.4 Increasing hASC Density Within 50 mg/mL Constructs Enhances and Accelerates 
Matrix Mineralization 
Cell seeding density has been demonstrated to regulate osteoblast cell proliferation and 
differentiation as well as cell-matrix interactions in 3D culture systems48. Increasing cell 
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densities between 3𝑥106 − 3𝑥107 cells/mL improves osteoblastic differentiation of 
both MG-63 osteosarcoma cell lines and MC3T3 osteoblast precursor cell lines 
encapsulated within dense telocollagen constructs after 3-4 weeks41, 48. Here, hASC 
were encapsulated within 50 mg/mL oligomer constructs at cell densities within this 
reported range to determine an optimum cell density for hASC-mediated bone 
regeneration.  
To evaluate the specific parameters for the rapid induction of mineralization, 
tissue constructs were cultured in osteogenic medium for 7 days then stained with 
Alizarin Red to observe the extent of mineral formation. As shown in Figure 6A, the 
number of small calcified nodules and size of larger calcified regions appeared to 
increase in a cell density-dependent fashion, suggesting that a cell density of 3𝑥107 
cells/mL is optimal for osteogenic differentiation of hASC. Additionally, cellular 
encapsulation at high densities appeared to accelerate mineral formation; the extent of 
matrix mineralization observed at 7 days within oligomer tissue constructs is 
comparable to what other groups have observed after 21 days using absorbable 
collagen sponges seeded with similar quantities of bone marrow-derived mesenchymal 
stem cells43. Dense oligomer tissue constructs encapsulated with high cell densities 
promote rapid matrix mineralization. 
Interestingly, cell-induced contraction was observed during culture with 
osteogenic medium across all cell seeding densities (Figure 6B). Whereas tissue 
constructs cultured in growth medium contracted by 7.9 ± 3.5%, those cultured in 
osteogenic medium contracted by 71.5 ± 3.7% on average with no significant difference 
between cell density groups (p = 0.959). These observations are similar to what other 
groups have found using high cell seeding densities in dense telocollagen constructs (70-
80% contraction after 7 days)40. The observed cell-induced contraction may be 
attributable to enhanced cellular proliferation and collagen production promoted by the 
components of osteogenic differentiation medium. Future work will investigate 
methods of reducing cellular contraction for these optimized culture parameters. For 
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example, recent studies in our group have shown that embedding cellularized, low fibril-
density oligomer collagen matrices within a surrounding tissue microenvironment 
prevents cell-mediated contraction (K. Buno, unpublished). Experiments will examine 
how embedding the tissue constructs within low-fibril-density matrices (1.5 mg/mL) 





Figure 6: hASC were encapsulated within 50 mg/mL collagen constructs with final cell 
densities of 3𝑥106, 1.5𝑥107, and 3𝑥107cells/mL. Constructs were cultured for 7 days 
with osteogenic medium. (A) Constructs were stained with Alizarin Red to observe 
mineralization. Scale bars = 50 µm. (B) Cell-induced contraction was observed for all 






3.5 Osteogenic Medium Optimized for Differentiation in 2D Culture Supports 
Osteogenic Differentiation of hASC in 3D 
A standard osteogenic medium formulation (DMEM growth medium supplemented with 
100 nM dexamethasone (Dex), 0.05 mM L-ascorbic acid-2-phosphate (AA), and 10 mM 
beta-glycerophosphate (BGP)49) was developed for the osteogenic differentiation of 
mesenchymal stem cells in 2D culture systems. This formulation has been applied for 
the osteogenic differentiation of hASC in 2D culture50 but not all components may be 
necessary for 3D culture systems with a pre-existing interstitial matrix. Each component 
of the standard osteogenic medium formulation was added separately to growth 
medium to determine the minimum combination of components necessary to create a 
strong osteogenic response of hASC in 3D culture.  
 HASC-encapsulated oligomer tissue constructs (1.5𝑥107 cells/mL, 50 mg/mL) 
were cultured for 7 days in growth medium supplemented with (i) Dex, (ii) AA, (iii) BGP, 
(iv) AA and BGP, or (v) complete osteogenic medium representing the standard 
formulation that contains all three components. Growth medium served as a control 
culture condition. Alizarin Red stain for calcified extracellular matrix was used as a 
histologic marker of osteogenic differentiation. There was an absence of calcification in 
tissue constructs cultured for 7 days in growth medium and growth medium 
supplemented with either Dex or AA (Figure 7). Disperse, large mineralized regions were 
observed in samples cultured with BGP-supplemented medium. The addition of both AA 
and BGP to growth medium increased the number and size distribution of calcified 
nodules. Qualitatively, samples cultured in complete osteogenic medium exhibit the 
largest calcified regions when compared to other culture conditions and also have 
several smaller nodules. These observations suggest that the standard osteogenic 
medium formulation produces the greatest osteogenic response of hASC in 3D culture. 
These results are consistent with published literature on the mechanism of action of 
each osteogenic medium component51. In combination, the osteogenic differentiation 
medium components induce cell proliferation and osteoblast differentiation via specific 
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gene expression, increase secretion and remodeling of type I collagen, and provide a 
source of phosphate ions for mineral formation51. From this study, it appears that 
standard osteogenic medium is appropriate for osteogenic differentiation of hASC 
within 3D collagen tissue constructs. 
 
 
Figure 7: Human ASC were seeded in 50 mg/mL collagen constructs with a final cell 
density of 1.5𝑥107 cells/mL. Constructs were cultured for 7 days with growth medium 
containing dexamethasone (Dex), ascorbic acid (AA), beta-glycerophosphate (BGP), AA + 
BGP, or complete osteogenic medium containing all three components. Constructs were 
stained with Alizarin Red to observe mineralization. Scale bars = 50 µm. 
 
3.6 Calcium Concentration in Osteogenic Medium Modulates Mineral Distribution 
and Quality 
The calcium to phosphate ratio of natural hydroxyapatite, as determined by its 
molecular structure, is 1.6752. Standard DMEM medium contains 1.8 mM calcium ions 
and osteogenic medium provides 10 mM phosphate ions, suggesting a disproportionate 
supply of ions critical for apatite formation. Ionic calcium levels of 8 mM in both growth 
and osteogenic medium have been shown to increase the quantity and rate of 
ossification during in vitro culture39. Tissue constructs were cultured in either the 
presence or absence of 8 mM ionic calcium to determine if calcium is a limiting factor 
for standard in vitro models of osteogenesis. The osteogenic behavior of hASC was 
assessed by examining the resulting matrix and mineral properties.  
Tissue constructs (50 mg/mL) encapsulated with hASC at 3𝑥107 cells/mL were 
cultured for 7 days in growth medium or osteogenic medium with and without of 8 mM 
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calcium chloride as a source of calcium ions. Alizarin Red stain was used to observe 
mineral deposition within the tissue constructs (Figure 8). Samples cultured with growth 
medium exhibit no calcified nodules. The addition of extracellular calcium to growth 
medium results in the presence of both small and medium-sized calcified nodules with a 
disperse but homogenous distribution throughout the construct. Samples cultured in 
standard osteogenic medium had a high concentration of both large and small calcified 
nodules at the periphery of the tissue construct but a low distribution at the core. 
Calcium-supplemented osteogenic medium increased the presence of mineralized 
matrix. Mineralized regions were surrounded by a general red hue in the matrix and had 
softer edges than those found in standard osteogenic conditions. Additionally, the 
peripheral effect observed in calcium-supplemented osteogenic medium was less 
distinct than what was observed for standard osteogenic medium. Calcium-
supplemented tissue constructs had a high distribution of mineralized regions at the 
edges of the construct but also throughout the core. These histological observations 
suggest that calcium concentration in culture medium modulates mineral distribution 
within the scaffold. These results are consistent with studies of calcium and phosphate 
ions as chemical signaling factors. Specifically, extracellular ionic calcium is an important 
regulator of cellular events in bone regeneration including cell proliferation, 
mineralization, and growth factor production in a variety of cell types53-55. Calcium 





Figure 8: Human ASC were encapsulated within 50 mg/mL collagen constructs at a 
density of 3𝑥107cells/mL. Tissue constructs were cultured for 7 days with growth 
medium or osteogenic medium, either alone or supplemented with 8 mM calcium. 
Alizarin Red was used to stain regions of matrix calcification at the center (top) and 
periphery (bottom) of the tissue constructs. Scale bars = 50 µm.  
 
MicroCT was utilized to further analyze the mineral distribution and quantify the 
mineralized volume fraction within hASC-encapsulated tissue constructs. Analysis was 
conducted at an early time point of 7 days to assess the capacity of the tissue construct 
to rapidly induce mineralization. 3D reconstruction of tissue constructs cultured with 
standard and calcium-supplemented osteogenic medium are shown in Figure 9A. The 3D 
reconstructions for tissue constructs cultured in standard osteogenic medium display 
disperse areas of radiographically dense regions throughout the construct with a greater 
distribution of dense regions at the periphery. The mineralized matrix observed in 
histological sections for these groups may not correspond to mature, dense minerals 
that can be observed radiographically. In contrast to the standard osteogenic conditions, 
calcium-supplemented groups exhibit dense regions around the periphery but also 
throughout the center of the tissue construct. The mineralized volume fraction 
(mineralized volume/total volume, %) of tissue constructs cultured in calcium-
supplemented osteogenic medium (3.03 ± 0.86%) was significantly greater (p = 0.0037) 
than for tissue constructs cultured in standard osteogenic medium (0.007 ± 0.001%) 
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(Figure 9B). An acellular construct cultured for 7 days in calcium-supplemented 
osteogenic medium had a mineralized volume fraction of 0.41 ± 0.18% (data not shown). 
The mineral distribution observed in hASC-seeded dense oligomer tissue constructs 
cultured in calcium-supplemented osteogenic medium is comparable at 1 week to what 
other groups have found in dense telocollagen constructs encapsulated with mouse 
osteoblasts after 4-7 weeks of culture with standard osteogenic medium41. Dense 
telocollagen constructs had mineralized volume fractions of 0.05% after incubation in 
simulated body fluid for 1 week56 and 0.22% after culture in osteogenic medium for 8 
weeks. Simulated body fluid is a medium formulation with ionic composition similar to 
what is found in blood plasma in vivo, with 2.5 mM calcium and 1.0 mM phosphate56. 
MicroCT confirmed that osteogenic medium supplemented with ionic calcium both 
expedites and increases the amount of mineralization observed at the periphery and the 




Figure 9: MicroCT was used to analyze the distribution of mineralized regions within 
tissue constructs (50 mg/mL, 3x107 hASC/mL) cultured for 7 days in osteogenic medium 
or osteogenic medium supplemented with 8 mM calcium chloride. (A) 3D reconstructed 
images for each culture condition show the distribution of radiographically dense, 
mineralized regions within tissue constructs. (B) The mineralized volume fraction (% 
mineralized volume/total volume) was significant greater in constructs cultured with 
both osteogenic medium and 8 mM calcium, indicated by the asterisk (p < 0.05). 
 
SEM was coupled with energy dispersive x-ray spectroscopy (EDX) to analyze the 
atomic composition of minerals found within the two groups. Three representative 
regions within a randomly-selected tissue construct were analyzed for each culture 
condition. The SEM micrographs of the two culture conditions further establish the 
increased presence of mineralized collagen resulting from calcium supplementation in 
osteogenic medium (Figure 10 A & B). Energy spectra obtained with EDX were used to 
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identify and quantify the atomic composition of the minerals found within the tissue 
constructs. Representative spectra and a summary table are shown in Figure 10 C & D 
and Figure 10E, respectively. Minerals present in samples cultured in standard 
osteogenic medium had a calcium to phosphate ratio (Ca:P) of 1.49 ± 0.13, in the range 
of values reported for amorphous calcium phosphate52. Amorphous calcium phosphate 
is a solid with nanometer-sized particles that convert to crystalline apatite with time52. 
This material has a role in matrix vesicle-mediated mineralization and represents an 
intermediate mineral phase in the development of mature hydroxyapatite57. Extending 
the culture duration may provide sufficient time for the amorphous mineral phase to 
mature. Minerals within tissue constructs cultured with calcium-supplemented 
osteogenic medium exhibit a Ca:P ratio of 1.69 ± 0.10, close to the 1.67 value 
characteristic of hydroxyapatite52. For comparison, telocollagen constructs encapsulated 
with mouse osteoblasts had a Ca:P ratio of 1.3 after 8 weeks of culture in osteogenic 
medium. Calcium supplementation may act to balance the ratio of ions presented to the 





Figure 10: SEM and EDX were used to visualize collagen fibril mineralization and quantify 
atomic composition of mineralized regions within tissue constructs (50 mg/mL, 3x107 
hASC/mL) cultured for 7 days in osteogenic medium (A, C) or osteogenic medium 
supplemented with 8 mM calcium chloride (B, D). (E) The atomic composition (atomic %) 
calculated from the spectra, and calcium-to-phosphate ratios, are summarized for all 
culture conditions. Values represent the average ± standard deviation calculated from 3 
representative areas. 
 
Mechanical analysis was performed on each culture condition to determine the 
relationship between matrix mineralization and compressive modulus. Acellular 
constructs cultured for 7 days in osteogenic medium supplemented with 8 mM calcium 
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chloride served as a control. As shown in Figure 11, the compressive modulus of tissue 
constructs cultured for 7 days in osteogenic medium supplemented with calcium (640.6 
± 120.6 kPa) was significantly greater (p = 0.001) than the modulus for those cultured in 
osteogenic medium (79.0 ± 15.3 kPa) and in growth medium (24.0 ± 10.0). Acellular 
constructs cultured for the same duration in calcium-supplemented osteogenic medium 
had a compressive modulus of 31.7 ± 15.9 kPa (data not shown). These differences may 
be attributable to the presence of newly-synthesized mineral found in osteogenic 
conditions, since extracellular matrix mineralization hardens the tissue23. The 
compressive modulus of calcium-supplemented tissue constructs reflects the 
differences in distribution, density, and presence of crystalline hydroxyapatite crystals 
previously observed with histology, microCT, and EDX. 
 These results suggest that calcium is a limiting factor for osteogenic culture 
systems in vitro, as calcium supplementation increased the distribution, density, and 
quality of the mineralized matrix. The ionic concentrations of calcium and phosphate 
used in the calcium-supplemented osteogenic medium (8 mM and 10 mM, respectively) 
are more evenly balanced than what are found in standard osteogenic medium (1.8 mM 
and 10 mM, respectively) but may not accurately represent the ionic concentrations 
found in vivo. Circulating blood plasma concentrations of calcium and phosphate are 
most closely approximated in vitro with simulated body fluid (SBF) which contains 2.5 
mM calcium and 1.0 mM phosphate58. However, SBF does not provide the additional 
molecules that would be found in the wound bed of a bone defect (such as steroids or 
vitamin C as mimicked in osteogenic medium)6. Additionally, ionic concentrations in a 
healing bone defect may be elevated in comparison to normal blood plasma resulting 
from hydroxyapatite crystal dissolution induced by the acidity of the wound bed59, 60. 
Future studies will be conducted to determine the rate and extent of mineralization 
using osteogenic medium with physiologic concentrations of calcium and phosphate but 
in vivo studies will be necessary to evaluate the bone regenerative capacity of the tissue 





Figure 11: Mechanical analysis was performed to determine the compressive modulus 
of tissue constructs (50 mg/mL, 3x107 cells/mL) after 7 days of culture in growth, 
osteogenic, or calcium-supplemented (8 mM) osteogenic medium. (A) Representative 
stress-strain curves for each culture condition. (B) Compressive modulus for constructs 
cultured in calcium-supplemented osteogenic medium was significantly greater than 
those found for growth and standard osteogenic conditions, indicated by the asterisk (p 
< 0.05).  
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CHAPTER 4. CONCLUSIONS 
4.1 Conclusions 
Overall, these results support the utilization of densified, self-assembling collagen-fibril 
matrices to meet the ideal design criteria for alveolar bone graft substitutes. The fibril 
microstructure and associated mechanical properties of self-assembled oligomers 
support cellular encapsulation with improved shape retention compared to 
conventional polymerizable collagen formulations. We have demonstrated that the 
suprafibrillar assembly of oligomer collagen also promotes the in vitro nucleation and 
growth of hydroxyapatite crystals to create integrated collagen-hydroxyapatite 
composite tissues with multi-scale structures similar to native bone. Densified oligomer 
collagen-fibril constructs with fibril densities of 50 mg/mL were found to have 
compressive moduli comparable to the unmineralized osteoid deposited during the 
natural bone healing process and could provide physical support to the alveolar bone 
defect. This work also validates the osteoconductive capacity of the cellularized tissue 
constructs, which may act as a bone regeneration template. Tissue constructs 
encapsulated with hASC exhibit rapid matrix mineralization, especially in culture 
conditions that supply similar concentrations of both calcium and phosphate ions. 
Analysis of the mineralized areas showed calcium and phosphorous with a ratio similar 
to that of mature hydroxyapatite in contrast to alternative collagen-based tissue 
constructs with minerals more similar to amorphous calcium phosphate, a potential 
precursors of hydroxyapatite40, 43. Mineralization within the oligomer tissue constructs 
was dispersed throughout the tissue construct after just 7 days of culture. The 
distribution and mineralized volume fraction were greater than what others have found 




vitro studies of cellularized oligomer collagen-fibril templates demonstrate the capacity 
of these materials to support the rapid production of mature minerals.   
The in vitro studies served as a proof-of-concept for the regenerative capacity of 
the template in vivo. This material also supports customization to create patient-specific 
templates to meet the NIDCR’s stated clinical need. The polymerizable, self-assembling 
oligomer collagen formulation chosen to create these tissue constructs accommodates 
customization via several avenues – including geometry, fibril density (and associated 
mechanical properties), and type and quantity of encapsulated cells – to rapidly 
generate materials specific for a given clinical application. For example, the rapidly self-
assembling oligomer solution facilitates injection and polymerization in vivo but it may 
also be used to quickly produce matrices with specified dimensions using customized 
molds.  In summary, this bone regeneration template is customizable for specific 
applications and may address a gap in the clinical landscape for alveolar bone grafting 
by supporting the rapid generation of high quality bone mineral in vitro.  
 
4.2 Future Studies 
Future in vitro studies utilizing these tissue constructs will seek to (i) address 
concerns with contraction, (ii) further define their ability promote bone regeneration in 
vitro, and (iii) determine their capacity for integration with and remodeling by host 
tissue. Firstly, studies will be conducted to address the contraction observed during 
culture in osteogenic conditions. Recent work in our lab has shown that embedding 
cellularized collagen matrices within a surrounding tissue microenvironment prevents 
cell-mediated contraction. Experiments will examine how tethering the tissue constructs 
within low fibril-density (1.5 mg/mL) matrices impacts the extent of contraction and 
osteogenesis. Additional in vitro studies will investigate the osteoconductive capacity of 
the tissue constructs, including determining the genetic markers expressed by hASC and 




compare the distribution and quality of mineral produced in tissue constructs cultured 
in calcium-supplemented osteogenic medium to that produced using osteogenic 
medium with physiologic ion concentrations. Conducting in vitro studies on the extent 
of matrix remodeling during cell-mediated mineralization will offer an opportunity to 
gain further insight into the ability for oligomer collagen-fibril matrices to be integrated 
and remodeled by cells. These studies will be conducted using a rapid high performance 
liquid chromatography-mass spectrometry method to identify and quantify specific non-
reducible (mature) crosslinks found in the tissue constructs.  
Finally, we will investigate the regenerative capacity of the tissue constructs in 
vivo. Preliminary in vivo studies indicate that low density (3.5 mg/mL) oligomer matrices 
with and without encapsulated mesenchymal stem cells readily integrate with 
surrounding host bone and promote significant bone regeneration in comparison to 
control calvaria defects (T. Smith, unpublished). These results suggest that the densified 
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